August 29, 2022
Novartis Pharma said on August 26 that its CAR-T cell therapy Kymriah (tisagenlecleucel) has obtained an additional indication of relapsed or refractory follicular lymphoma in Japan. The green light is based on data from a global pivotal PII study, ELARA,...read more